RE: scancell11 Feb 2022 18:58
Interesting article but they are talking recently IPO’d ventures not longstanding AIM plays. Sclp/REDX fall into the latter. Both have Redmile backing them and are not part of the US bubble. Both have £40mill + cash but the baby seems to get thrown out with the bath water. Understandable IMO.
Don’t get me wrong, I think adding the dips is a mistake and this includes pharma biotech, but residual value exists with Scancell, REDX and to a lesser extent Angle.
On the other hand buying in at a discount? Hmmm, maybe they have a little further to fall? No quick bounce backs me thinks. That goes beyond biotech also.
As I say good for me!